Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CUE

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Cue Biopharma

CUE
Current price
0.77 USD -0.03 USD (-3.77%)
Last closed 0.80 USD
ISIN US22978P1066
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 59 978 524 USD
Yield for 12 month -17.63 %
1Y
3Y
5Y
10Y
15Y
CUE
21.11.2021 - 28.11.2021

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Address: 40 Guest Street, Boston, MA, United States, 02135

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.00 USD

P/E Ratio

Dividend Yield

Financials CUE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+9 287 000 USD

Last Year

+5 490 000 USD

Current Quarter

+421 000 USD

Last Quarter

+1 576 000 USD

Current Year

+9 287 000 USD

Last Year

-32 607 000 USD

Current Quarter

+421 000 USD

Last Quarter

+1 576 000 USD
EBITDA -40 825 000 USD
Operating Margin TTM -2 921.38 %
Price to Earnings
Return On Assets TTM -67.62 %
PEG Ratio
Return On Equity TTM -221.66 %
Wall Street Target Price 4.00 USD
Revenue TTM 7 991 000 USD
Book Value 0.11 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -75.50 %
Dividend Yield
Gross Profit TTM -26 652 000 USD
Earnings per share -0.64 USD
Diluted Eps TTM -0.64 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CUE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.63
Price Sales TTM 7.51
Enterprise Value EBITDA -1.76
Price Book MRQ 8.97

Technical Indicators CUE

For 52 Weeks

0.45 USD 1.99 USD
50 Day MA 0.70 USD
Shares Short Prior Month 831 592
200 Day MA 1.04 USD
Short Ratio 4.98
Shares Short 1 161 283
Short Percent 1.11 %